NTP, part of South Africa's state nuclear corporation, processes molybdenum-99 and other isotopes from the SAFARI-1 reactor and was the first major producer to switch to low-enriched uranium targets.
NTP Radioisotopes, a subsidiary of the South African Nuclear Energy Corporation, irradiates targets in the SAFARI-1 research reactor at Pelindaba and processes molybdenum-99, iodine-131 and lutetium-177 for export to generator makers and radiopharmacies worldwide. It converted its molybdenum production to low-enriched uranium targets ahead of other producers. Regulator-ordered shutdowns of its processing facility in 2017 and 2018 removed a large share of world molybdenum-99 supply for months and showed how few processors there are.
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Research reactors for medical isotopes (Mo-99, Lu-177, I-131) and the tag manufacturing-wave.
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Research reactors for medical isotopes (Mo-99, Lu-177, I-131) and the tag manufacturing-wave.
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Research reactors for medical isotopes (Mo-99, Lu-177, I-131) and the tag manufacturing-wave.
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Research reactors for medical isotopes (Mo-99, Lu-177, I-131) and the tag manufacturing-wave.
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225) and the tag manufacturing-wave.
Shares Research reactors for medical isotopes (Mo-99, Lu-177, I-131) and the tag manufacturing-wave.
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Research reactors for medical isotopes (Mo-99, Lu-177, I-131).